Christopher R. Fenimore - SVP Finance & CFO at Regeneron Pharmaceuticals, Inc.

Insider Transactions and Holdings

Entity Type
Individual
Role
SVP Finance & CFO
Stock Symbol
REGN on Nasdaq
Industry
Pharmaceutical Preparations
All Insider Reports
All Insider Reports

Christopher R. Fenimore - trading volume in the past year for Regeneron Pharmaceuticals, Inc.

Holdings reported by Christopher R. Fenimore for Regeneron Pharmaceuticals, Inc.

Class Num Shares Value Price $ Report Date Ownership Underlying Class Underlying Amount
Common Stock 14,372 $13.7 M $955.00 Feb 9, 2024 Direct
Common Stock 4,269 $4.08 M $955.00 Feb 9, 2024 2022 GRAT
Common Stock 1,897 $1.81 M $955.00 Feb 9, 2024 By Trust
Common Stock 1,499 $1.43 M $955.00 Feb 9, 2024 By 401(k) Plan
Common Stock 1,473 $1.41 M $955.00 Feb 9, 2024 2021 GRAT
Common Stock 461 $440 K $955.00 Feb 9, 2024 by Trust for Daugh
Common Stock 460 $439 K $955.00 Feb 9, 2024 by Trust for Son
Non-Qualified Stock Option (right to buy) 0 Jan 23, 2024 Direct Common Stock

Transactions reported by Christopher R. Fenimore for Regeneron Pharmaceuticals, Inc.

Sym Class Transaction % Value $ Price $ Shares Shares After Date Ownership